title: Clinical Performance of Whole-Body 18F-FDG PET/Dixon-VIBE, T1-Weighted, and T2-Weighted MRI Protocol in Colorectal Cancer.
abstract: OBJECTIVE
  The aim of this study was to investigate the clinical performance of whole-body (18)F-FDG PET/Dixon-volume-interpolated breath-hold examination (Dixon-VIBE), T1-weighted, and T2-weighted MRI protocol in patients with colorectal cancer.
  
  
  METHODS
  A total of 59 patients with colorectal cancer were enrolled in this study. Each patient had one of the following clinical conditions: initial stage before therapy, stage after neoadjuvant therapy, suspicious colorectal liver metastases, and colorectal liver metastases after chemotherapy. Fourteen patients had primary colorectal cancer, whereas 38 patients had a total of 132 hepatic lesions, 53 lesions existed before chemotherapy, and 79 lesions appeared after chemotherapy. The primary stage and metastases images were obtained using our PET/Dixon-VIBE/T1/T2 MRI protocol and were analyzed by 2 nuclear medicine physicians. Diagnostic accuracy was compared with contrast-enhanced MRI images, which were based on surgical pathology results.
  
  
  RESULTS
  The sensitivity of our imaging protocol for primary colorectal cancer was 100% (14/14). T and N stage both showed 92.9% (13/14) accuracy. Of all 132 hepatic lesions, 115 metastatic lesions were analyzed, and 17 benign lesions were excluded (6 were during pretreatment cases, and 11 were during posttreatment cases). In pretreatment metastatic lesions (n = 47), the sensitivities of our protocol and dedicated MRI were 95.7% (45/47) and 100% (47/47), respectively. In posttreatment lesions (n = 68), sensitivities of our protocol and dedicated MRI were 75% (51/68) and 91.2% (62/68), respectively.
  
  
  CONCLUSIONS
  Whole-body PET/Dixon-VIBE/T1/T2 MRI protocol is clinically useful for TNM staging and chemonaive hepatic metastasis in colorectal cancer.
authors.affiliation: From the *Department of Nuclear Medicine, College of Medicine, Seoul National University; †Department of Nuclear Medicine, Korea University College of Medicine, Guro Hospital; ‡Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, §Department of Biomedical Sciences, ∥Cancer Research Institute, ¶Department of Surgery, and **Department of Radiology, College of Medicine, Seoul National University, Seoul, South Korea; and ††Department of Radiological Science, University of California, Irvine, CA.
authors.forename: Soo Jin
authors.initials: SJ
authors.lastname: Lee
authors.forename: Hyo Jung
authors.initials: HJ
authors.lastname: Seo
authors.forename: Keon Wook
authors.initials: KW
authors.lastname: Kang
authors.forename: Seung-Yong
authors.initials: SY
authors.lastname: Jeong
authors.forename: Nam-Joon
authors.initials: NJ
authors.lastname: Yi
authors.forename: Jeong Min
authors.initials: JM
authors.lastname: Lee
authors.forename: June-Key
authors.initials: JK
authors.lastname: Chung
authors.forename: E
authors.initials: E
authors.lastname: Edmund Kim
authors.forename: Jin Chul
authors.initials: JC
authors.lastname: Paeng
authors.forename: Gi Jeong
authors.initials: GJ
authors.lastname: Cheon
authors.forename: Dong Soo
authors.initials: DS
authors.lastname: Lee
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D015179:Colorectal Neoplasms / Q000000981:diagnostic imaging* / Q000473:pathology; D038524:Diffusion Magnetic Resonance Imaging; D005260:Female; D019788:Fluorodeoxyglucose F18; D006801:Humans; D008297:Male; D008875:Middle Aged; D049268:Positron-Emission Tomography; D019275:Radiopharmaceuticals; D051598:Whole Body Imaging
chemical_list: D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18